VECT-HORUS Raises €6.7 Million to Further Develop Its VECTrans® Platform
09/08/20, 1:08 PM
Location
marseilleMoney raised
€6 million
VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, has announced that it has raised €6.7 million. In this new round of financing participated historic shareholders and also new entrants. It will strengthen the company's equity capital, enabling it to develop its programs and the upcoming clinical trial of its first theragnostic agent (contraction of the terms "therapeutic" and "diagnostic").
Company Info
Location
marseille, provence alpes côte d'azur, france
Additional Info
Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumours. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (first and foremost the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more Vect-Horus, visit www.vect-horus.com.